Q-omics provides the consensus-scored KRT18P46 profile across patient tissues and cancer cell-line models. KRT18P46 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, KRT18P46 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, KRT18P46 RNA expression shows 5,863 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, LUAD, and STAD as cancer lineages where KRT18P46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P46 survival associations across molecular data types. KRT18P46 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P46 RNA expression–survival associations across cancer types. High KRT18P46 expression shows unfavorable associations in ESCA, BRCA, SKCM, STAD, THYM and OV. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for KRT18P46 RNA expression.
This table summarizes KRT18P46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P46 shows lower tumor expression in LIHC and higher tumor expression in LUAD, BRCA, STAD and KIRC. The LUAD box plot shows higher KRT18P46 RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p = .024).
This table shows molecular features associated with KRT18P46 in patient tissues and cancer cell lines. In patient samples, KRT18P46 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
